Effects of personalized diets by prediction of glycemic responses on glycemic control and metabolic health in newly diagnosed T2DM: a randomized dietary intervention pilot trial
Rein et al.
The finding, in our words
In a crossover trial of 23 adults with newly diagnosed type 2 diabetes, a personalised diet based on predicted postprandial glucose responses improved continuous glucose monitoring measures significantly more than a Mediterranean diet, including lower average postprandial glucose response and less time in hyperglycaemia. A six-month follow-up of the personalised diet further improved glycaemic control and metabolic health, supporting its clinical utility for decentralised diabetes management.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
A six-month randomised trial in 225 adults with prediabetes showed that a personalised postprandial-targeting diet, guided by a machine-learning algorithm integrating microbiome data, reduced daily time with glucose above 140 mg/dL and HbA1c significantly more than a Mediterranean diet, with benefits persisting at 12 months. The study illustrates how continuous glucose monitoring and smartphone-based dietary logging can enable patient-centric, decentralised nutritional interventions for glycaemic control.
Decentralised monitoring of people with type 2 diabetes using continuous glucose monitoring and a hybrid smartwatch was feasible, with high participant retention and successful collection of glucose, heart rate, activity, sleep and GPS data via a study app.
A fully remote decentralised clinical trial in Danish adults with type 2 diabetes demonstrated operational feasibility with rapid recruitment, high retention (87 percent), and excellent adherence to continuous glucose monitoring (95 percent achieving ≥70 percent data coverage) and telemedicine visits (97 percent). Activity tracker adherence was poor (12 percent) due to technical issues, but remote safety monitoring was effective with no unexpected adverse events, supporting the viability of remote diabetes management.
In a Phase 1 crossover study of etrasimod, self-collected blood microsamples yielded pharmacokinetic exposures comparable to conventional venous sampling, both with and without participant practice sessions. Continuous wearable sensors concurrently enabled real-time remote monitoring of safety vital signs and electrocardiograms, demonstrating the viability of hybrid decentralised designs in early-phase clinical trials.
This review assesses wearable sensors for the continuous biochemical monitoring of body fluids such as sweat, saliva and interstitial fluid, confirming their potential for decentralised healthcare through pilot trials. It emphasises that successful clinical translation depends on large-scale validation and the integration of ethical and sociocultural considerations.